STOCK TITAN

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has received regulatory approval to initiate a Phase 2 clinical trial for DM199, its proprietary recombinant serine protease, in the treatment of preeclampsia. The South African Health Products Regulatory Authority (SAHPRA) has approved the planned two-part study, which will be conducted at Tygerberg Hospital in Cape Town, South Africa. Prof. Catherine Cluver, MD, PhD will lead the investigator-sponsored trial as principal investigator.

The company expects to begin dosing in the fourth quarter of 2024, with top-line results for Part 1a anticipated in the first half of 2025. DiaMedica believes DM199 has the potential to be a disease-modifying therapy for preeclampsia, targeting placental perfusion, fetal growth, maternal blood pressure, and endothelial health.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) ha ricevuto l'approvazione regolatoria per avviare un trial clinico di Fase 2 per DM199, il suo proteasi serina ricombinante proprietario, nel trattamento della preeclampsia. L'Autorità Regolatoria dei Prodotti Sanitari del Sud Africa (SAHPRA) ha approvato lo studio pianificato in due parti, che sarà condotto presso l'Ospedale di Tygerberg a Città del Capo, Sud Africa. La Prof.ssa Catherine Cluver, MD, PhD sarà la responsabile dello studio sponsorizzato dagli investigatori.

L'azienda prevede di iniziare la somministrazione nel quarto trimestre del 2024, con i risultati preliminari per la Parte 1a attesi nel primo semestre del 2025. DiaMedica crede che DM199 abbia il potenziale per essere una terapia modificante la malattia per la preeclampsia, mirando alla perfusione placentare, alla crescita fetale, alla pressione sanguigna materna e alla salute endoteliale.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) ha recibido la aprobación regulatoria para iniciar un ensayo clínico de Fase 2 para DM199, su proteasa de serina recombinante de propiedad, en el tratamiento de la preeclampsia. La Autoridad Reguladora de Productos de Salud de Sudáfrica (SAHPRA) ha aprobado el estudio planificado en dos partes, que se llevará a cabo en el Hospital de Tygerberg en Ciudad del Cabo, Sudáfrica. La Prof. Catherine Cluver, MD, PhD será la investigadora principal en el ensayo patrocinado por investigadores.

La empresa espera comenzar la dosificación en el cuarto trimestre de 2024, con los resultados principales de la Parte 1a anticipados para la primera mitad de 2025. DiaMedica cree que DM199 tiene el potencial de ser una terapia modificadora de la enfermedad para la preeclampsia, enfocándose en la perfusión placentaria, el crecimiento fetal, la presión arterial materna y la salud endotelial.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC)는 2상 임상 시험을 시작하기 위한 규제 승인을 받았습니다. 이 시험은 자사의 독점 재조합 세린 프로테아제 DM199를 자간증 치료에 사용할 예정입니다. 남아프리카 보건 제품 규제 당국(SAHPRA)은 케이프타운의 타이거버그 병원에서 실시될 예정인 두 부분으로 나누어진 연구를 승인했습니다. 캐서린 클루버 박사(MD, PhD)가 주 연구 책임자로 이 시험을 이끌 것입니다.

회사는 2024년 4분기에 투여를 시작할 것으로 예상하며, 1a 부분의 주요 결과는 2025년 상반기에 나올 것으로 보입니다. DiaMedica는 DM199가 자간증에 대해 질병 수정 치료제가 될 가능성이 있다고 믿고 있으며, 유도태반관류, 태아 성장, 모체혈압 및 내피 건강에 목표를 두고 있습니다.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) a reçu l'approbation réglementaire pour initier un essai clinique de phase 2 pour DM199, sa protéase sérique recombinante de propriété, dans le traitement de la prééclampsie. L'Autorité réglementaire sud-africaine des produits de santé (SAHPRA) a approuvé l'étude en deux parties prévue, qui sera réalisée à l'hôpital de Tygerberg à Cape Town, Afrique du Sud. Le Professeur Catherine Cluver, MD, PhD, dirigera l'essai sponsorisé par les enquêteurs en tant qu'investigateur principal.

L'entreprise s'attend à commencer à doser au quatrième trimestre 2024, avec des résultats préliminaires pour la partie 1a prévus dans la première moitié de 2025. DiaMedica croit que DM199 a le potentiel d'être une thérapie modifiant la maladie pour la prééclampsie, ciblant la perfusion placentaire, la croissance fœtale, la pression artérielle maternelle et la santé endothéliale.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) hat die regulatorische Genehmigung erhalten, um eine Phase-2-Studie für DM199, sein proprietäres rekombinantes Serinprotease, zur Behandlung von Preeclampsie zu beginnen. Die südafrikanische Arzneimittelbehörde (SAHPRA) hat die geplante zweigeteilte Studie genehmigt, die im Tygerberg-Krankenhaus in Kapstadt, Südafrika, durchgeführt wird. Prof. Catherine Cluver, MD, PhD wird die als Prüfer geförderte Studie als Hauptprüfer leiten.

Das Unternehmen erwartet, die Dosen im vierten Quartal 2024 zu beginnen, wobei die Ergebnisse für Teil 1a im ersten Halbjahr 2025 erwartet werden. DiaMedica ist der Ansicht, dass DM199 das Potenzial hat, eine krankheitsmodifizierende Therapie für Preeclampsie zu sein, die auf die Plazentaperfusion, das fetale Wachstum, den Blutdruck der Mutter und die endotheliale Gesundheit zielt.

Positive
  • Regulatory approval received for Phase 2 clinical trial of DM199 in preeclampsia
  • Dosing expected to commence in Q4 2024
  • Top-line results for Part 1a anticipated in H1 2025
  • Potential to be the first therapeutic option for preeclampsia
Negative
  • None.

Insights

This regulatory approval for DiaMedica Therapeutics to begin a Phase 2 trial of DM199 for preeclampsia treatment is a significant milestone. Preeclampsia is a serious pregnancy complication with treatment options, so a potential new therapy could be groundbreaking. Key points to consider:

  • The trial will be conducted in South Africa, potentially accelerating recruitment in a high-risk population
  • Preliminary results are expected in H1 2025, providing a near-term catalyst
  • DM199's mechanism targets multiple aspects of preeclampsia pathophysiology, including placental perfusion, fetal growth and maternal blood pressure
  • If successful, this could be the first disease-modifying therapy for preeclampsia

While promising, investors should note that Phase 2 trials still carry significant risk. The $191 million market cap suggests the market is pricing in some success, but there's potential for significant upside if the data is positive.

This news represents a positive development for DiaMedica Therapeutics, potentially expanding their pipeline and addressable market. Key financial implications include:

  • No immediate revenue impact, but positive data could drive valuation
  • Increased R&D expenses expected as the trial progresses
  • Potential for partnerships or increased investor interest if preliminary data is promising
  • The global preeclampsia therapeutics market is projected to reach $1.8 billion by 2027, offering significant revenue potential

With a market cap of $191 million, DMAC is still a small-cap biotech stock. This news could attract more institutional investors, potentially improving liquidity. However, the company will likely need additional funding to advance DM199 through later-stage trials if successful. Investors should monitor cash burn and potential dilution risks.

  • Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced regulatory approval has been received to initiate a Phase 2 clinical trial with DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia. The South African Health Products Regulatory Authority (SAHPRA) has issued approval to proceed with the planned two-part Phase 2 study, which will be conducted as an investigator-sponsored trial at Tygerberg Hospital in Cape Town, South Africa, under the leadership of Prof. Catherine Cluver, MD, PhD as the principal investigator. DiaMedica previously received approval from the Health Research Ethics Committee at Stellenbosch University on June 26, 2024. The Company anticipates dosing will commence in the fourth quarter of 2024. Top-line results for Part 1a of the study are expected in the first half of 2025.

“We are excited to receive regulatory approval and are eager to advance our Phase 2 clinical trial of DM199 for preeclampsia.” said Rick Pauls, President and Chief Executive Officer of DiaMedica. “This trial marks a significant milestone in our efforts to develop the first therapeutic option for this serious unmet medical need.”

Dr. Lorianne Masuoka, Chief Medical Officer of DiaMedica, added, “We believe that DM199 has the potential to be a disease-modifying therapy for preeclampsia, based on its mechanism of action. Specifically, we believe that DM199 targets and has the potential to improve placental perfusion and enhance fetal growth, while also lowering maternal blood pressure and improving endothelial health. The data anticipated from Part 1a of the study should provide strong proof of concept for DM199's potential as a disease-modifying therapy, thereby increasing the likelihood of prolongation of gestational days and a healthier baby and mother.”

About Preeclampsia

Preeclampsia is a serious pregnancy disorder that typically develops after the 20th week of gestation, characterized by high blood pressure and damage to organ systems, often the kidneys and liver. Affecting up to 8% of pregnancies worldwide, preeclampsia can pose significant risks to both the mother and baby, including risk of stroke, placental abruption, progression to eclampsia, premature delivery and death. Symptoms may include severe headaches, vision changes, upper abdominal pain and swelling in the hands and face. Delivery of the baby, often very prematurely, is the only available option for stopping the progression of preeclampsia. Women who have had preeclampsia have three to four times the risk of high blood pressure and double the risk for heart disease and stroke. There are currently no approved therapeutics for preeclampsia in the United States or Europe.

About the Preeclampsia Phase 2 Trial

This Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 in treating preeclampsia will be conducted at the Tygerberg Hospital, Cape Town, South Africa (SA), under the direction of Catherine Cluver, MD, PhD, Professor of Maternal/Fetal Medicine, Stellenbosch University, Stellenbosch, SA, in collaboration with DiaMedica. This trial will enroll up to 90 women with preeclampsia and potentially 30 subjects with fetal growth restriction. Dosing is expected to commence in the fourth quarter of 2024 and Part 1a topline study results are anticipated in the first half of 2025 and are intended to demonstrate whether DM199 is safe, lowers maternal blood pressure and dilates intrauterine arteries to increase placental blood flow.

About DM199

DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for acute ischemic stroke and preeclampsia. KLK1 is a serine protease enzyme that plays an important role in the regulation of diverse physiological processes via a molecular mechanism that increases production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factor. In preeclampsia, DM199 is intended to lower maternal blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta. In the case of acute ischemic stroke, in which DiaMedica is also studying the use of DM199, DM199 is intended to enhance blood flow and boost neuronal survival in the ischemic penumbra by dilating arterioles surrounding the site of the vascular occlusion and inhibition of apoptosis (neuronal cell death) while also facilitating neuronal remodeling through the promotion of angiogenesis.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management’s current expectations. When used in this press release, the words “anticipates,” “believes,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” or “will,” the negative of these words or such variations thereon or comparable terminology, and the use of future dates are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release include statements regarding DiaMedica’s expectations regarding the timing for commencement of dosing, number of enrollees and top-line results for Part 1a of the preeclampsia Phase 2 investigator-sponsored trial and anticipated clinical benefits and success of DM199 for the treatment of preeclampsia and acute ischemic stroke. Such statements and information reflect management’s current view and DiaMedica undertakes no obligation to update or revise any of these statements or information. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, risks and uncertainties relating to the DM199 Phase 2 investigator-sponsored trial for preeclampsia and the timing thereof, including for dosing and top-line results for Part 1a of the study, and the number of patients to be enrolled; the Company’s ReMEDy2 trial for acute ischemic stroke and the timing thereof, including site activations and enrollment; and regulatory applications and related filing and approval timelines; the possibility of adverse events associated with or unfavorable results from the trials; the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials; the ability to conduct successful clinical testing of DM199 and within anticipated parameters, enrollment numbers, costs and timeframes; the adaptive design of the ReMEDy2 trial and the possibility that the targeted enrollment and other aspects of the trial could change depending upon certain factors, including the statistical plan, additional input from the FDA and the blinded interim analysis; the perceived benefits of DM199 over any existing treatment options; the potential direct or indirect impact of COVID-19, hospital and medical facility staffing shortages, and worldwide global supply chain shortages on DiaMedica’s business and clinical trials, including the preeclampsia Phase 2 investigator-sponsored trial and the ReMEDy2 trial, and in particular site activation and enrollment goals and timing; DiaMedica’s reliance on collaboration with third parties to conduct clinical trials; DiaMedica’s ability to continue to obtain funding for its operations, including funding necessary to complete current and planned clinical trials and obtain regulatory approvals for DM199 for acute ischemic stroke and preeclampsia, and the risks identified under the heading “Risk Factors” in DiaMedica’s annual report on Form 10-K for the fiscal year ended December 31, 2023 and subsequent reports filed with the U.S. Securities and Exchange Commission, including its most recent quarterly report on Form 10-Q for the quarterly period ended June 30, 2024. The forward-looking information contained in this press release represents the expectations of DiaMedica as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

For Investor Inquiries:

Mike Moyer

Managing Director, LifeSci Advisors, LLC

mmoyer@lifesciadvisors.com

Source: DiaMedica Therapeutics Inc.

FAQ

What is the purpose of DiaMedica's Phase 2 trial for DM199 (DMAC)?

The Phase 2 trial aims to evaluate DM199, DiaMedica's proprietary recombinant serine protease, as a potential treatment for preeclampsia.

When is DiaMedica (DMAC) expected to begin dosing in the Phase 2 trial for DM199?

DiaMedica anticipates dosing will commence in the fourth quarter of 2024 for the Phase 2 trial of DM199 in preeclampsia.

Where will DiaMedica's Phase 2 trial for DM199 (DMAC) be conducted?

The Phase 2 trial will be conducted at Tygerberg Hospital in Cape Town, South Africa, as an investigator-sponsored trial.

What are the potential benefits of DM199 (DMAC) in treating preeclampsia?

DiaMedica believes DM199 may improve placental perfusion, enhance fetal growth, lower maternal blood pressure, and improve endothelial health in preeclampsia patients.

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

DMAC Rankings

DMAC Latest News

DMAC Stock Data

182.30M
42.75M
26.23%
30.55%
0.43%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MINNEAPOLIS